Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2020 Nov 1.

Published in final edited form as: Cancer Chemother Pharmacol. 2019 Sep 3;84(5):993–1001. doi: 10.1007/s00280-019-03939-7

Figure 3: — Monte Carlo simulations of the final model. A. Median concentrations following single dose of siltuximab (11 mg/kg) for a 70 kg subject healthy subject, with Castleman’s disease, or with other tumors. B. Steady state concentrations for Castleman’s disease patients receiving siltuximab 11 mg/kg every 3 weeks. C. Steady state concentrations for patients with other cancers receiving siltuximab 11 mg/kg every 3 weeks. Data represent median and interquartile range (25-75%).

Figure 3: — Monte Carlo simulations of the final model. A. Median concentrations following single dose of siltuximab (11 mg/kg) for a 70 kg subject healthy subject, with Castleman’s disease, or with other tumors. B. Steady state concentrations for Castleman’s disease patients receiving siltuximab 11 mg/kg every 3 weeks. C. Steady state concentrations for patients with other cancers receiving siltuximab 11 mg/kg every 3 weeks. Data represent median and interquartile range (25-75%).